



ASX ANNOUNCEMENT

15 June 2007

GLOBAL WOUND CARE EXPERT TO ADVISE TISSUE THERAPIES

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has appointed internationally renowned wound care expert, Professor Keith Harding of Cardiff University, as an expert advisor for the Company's upcoming VitroGro® human trials.

Professor Harding will provide expert wound care product development advice to Tissue Therapies under a formal consulting agreement, with a particular focus on the development of VitroGro® products to manage diabetic, venous and pressure ulcers.

Tissue Therapies Chief Executive, Dr Steven Mercer said that Professor Harding is recognised as one of the leading expert wound care researchers and clinicians in the world today.

"I am delighted that Tissue Therapies will have the benefit of the world class expertise and experience of Professor Keith Harding. His consulting advice will provide substantial practical scientific, clinical and commercial benefits for the VitroGro® product development program", Dr Mercer said.

VitroGro® inventor and Tissue Therapies' Chief Scientific Officer Professor Zee Upton added "I am particularly pleased that Professor Harding has agreed to provide Tissue Therapies and our scientific and research teams with his considerable expertise. I have no doubt that this will materially benefit our applied research and clinical trial work," she said.

Professor Harding graduated in medicine from the University of Birmingham before undertaking training in surgery and family medicine. In 1991 he became Director of Wound Healing Research Unit at the University of Wales, College of Medicine in Cardiff.

Providing background for the clinical trials that Dr Harding will help oversee, Dr Mercer explained that diabetic and venous ulcers together represent a world wide market of more than US\$2 billion in annual wound healing product demand and this is growing at a conservative estimate of 11% per annum.

"I am absolutely confident that the speed with which Tissue Therapies will be able to offer new treatments for these substantial areas of need will be accelerated by the involvement of Professor Harding in our planning and delivery of new technology wound treatments", he said.

The strategic appointment of Professor Harding adds to the growing team of clinical wound care experts now assisting with clinical trials and product development aimed at introducing VitroGro® wound care products into the global wound care market. Professor Harding has worked on a number of clinical trial projects with Drs Sibbald and Douglas Queen, the researchers who will conduct the clinical trial of VitroGro® for completion by December 2007 (see TT ASX Announcement “Canadian Clinical Trial”, 22 May 2007). Together with Dr Gary Sibbald, Professor Harding is a member of the organising committee for the World Union of Wound Healing Societies Meeting in Toronto during 2008.

Dr Mercer said that the involvement of a number of world-expert key opinion leaders in clinical trials and product development was also an important element of the Company’s strategy for market penetration of VitroGro® wound care products following regulatory approval in important world markets.

ENDS

For more information: Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: 07 3839 9938

Email: s.mercer@tissuetherapies.com

ADDITIONAL INFORMATION

About Professor Keith Harding MB MRCGP FRCS:

Professor of Rehabilitation Medicine (Wound Healing)/Director Wound Healing Research Unit
Tel: +44 (0)29 20682176 Fax: +44 (0)29 20754217

Professor Harding graduated in medicine from the University of Birmingham. He is trained in general surgery and in family medicine and has a longstanding interest in wound healing. As Clinical Director of the Wound Healing Research Unit, he is currently Head of the Department of Surgery and Professor of Rehabilitation Medicine (Wound Healing).

He specialises in treating patients with wound healing problems and has authored over 250 publications and written a number of text books on wound healing that are widely considered to be definitive clinical reference books.

Professor Harding was the First President of the European Pressure Ulcer Advisory Panel, First Recorder of the European Wound Management Association and is currently President of the European Tissue Repair Society.

As well as conducting his own research, Professor Harding has managed a large number of large wound treatment clinical trials for large international companies and is often invited to lecture on wound management at scientific and clinical meetings.

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com